Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« What About Mental Health Expectancy? | Main | The Brain Imaging Bottleneck »

March 17, 2003

Cogniceuticals to Enhance Memory

Email This Entry

Posted by Zack Lynch

Advancing research powered by a tremendous market opportunity promises to help solve a number of memory related problems such as mild cognitive impairment, Alzheimer's, schizophrenia and Parkinson's.  Although current technologies are still in their infancy, the continued focus on enhancing human cognition will only grow in importance, especially as life spans get longer.


The potential to use cogniceuticals to accelerate learning and knowledge acquisition makes the market for the technologies extensive.  The development of effective cogniceuticals may provide individuals and organizations a new way to achieve competitive advantage in the coming decades.

Comments (0) | Category: Cogniceuticals



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
NIO Unveils Top 10 Neuroscience Trends for 2009
NIO CEO Media Tour in NYC Gets Results
O Neurocaster
Manuscript Sent to Japan
2009 Stem Cell Trendsetters in Neurology and Psychiatry
Mental Health Parity Legislation Passes within Financial Package
Holy Neurofinancial Meltdown Bernanke
Interest in Neuropolicy Grows